Can Tucatinib be purchased abroad? How much does it cost?

Tucatinib (Tucatinib) is a highly selective, oral, small-molecule tyrosine kinase inhibitor that specifically targets HER2-positive breast cancer. This drug blocks the growth and spread of cancer cells by inhibiting the HER2 signaling pathway, and has shown significant efficacy in the treatment of advanced or metastatic HER2 positive breast cancer. Tucatinib is usually used in combination with other drugs, such as trastuzumab (trastuzumab) and capecitabine (capecitabine), which significantly prolongs the progression-free survival and overall survival of patients, becoming an important treatment option for patients with HER2 positive breast cancer.

Currently, tucatinib (tucatinib) has not been launched in mainland China. This means that domestic patients cannot purchase the drug through formal channels and must rely on overseas channels to obtain it. This is a challenge for many patients, as purchasing medications through overseas channels involves complex procedures and high costs.

Abroad, Tucatinib has two options: original drug and generic drug. Original drugs are usually produced by European pharmaceutical companies and are very expensive. The monthly treatment cost can reach tens of thousands of yuan. Such a price is a huge financial burden for many patients and families.

In contrast, generic drugs offer a more economical option. The price of generic drugs produced in Laos and Bangladesh is around three to four thousand yuan. Although low in price, these generic drugs are basically the same as the original drugs in terms of drug ingredients and efficacy, providing a feasible treatment option for patients with limited financial conditions. Patients can obtain these generic drugs through some international drug purchasing platforms or directly contact overseas pharmacies, but it should be noted that these channels are not always reliable and caution is required when purchasing.

In short, althoughtucatinib has not yet been launched in mainland China, domestic patients can still purchase the drug through overseas channels, but there are certain challenges in both price and purchase channels. In order to reduce the financial burden on patients and improve the accessibility of the drug, many people have called for accelerating the approval and marketing process of tucatinib (tucatinib) in the country. This will help more patients with HER2-positive breast cancer receive effective treatment and improve their quality of life.